BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer
about
sameAs
BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status.Markers of resistance to anti-EGFR therapy in colorectal cancerDetection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodologySerrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapyMolecular profile of colorectal cancer in Indonesia: is there another pathway?Animal models of colorectal cancerMolecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveThe molecular background of mucinous carcinoma beyond MUC2Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigeneticsAllele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutationSmoking and colorectal cancer in Lynch syndrome: results from the Colon Cancer Family Registry and the University of Texas M.D. Anderson Cancer Center.Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based studyUtility of p16 immunohistochemistry for the identification of Lynch syndromeScreening for mismatch repair deficiency in colorectal cancer: data from three academic medical centers.Genomic and epigenetic instability in colorectal cancer pathogenesis.Epigenetic changes (aberrant DNA methylation) in colorectal neoplasia.Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.Hereditary colon cancer: lynch syndromeMolecular genetic analysis of 103 sporadic colorectal tumours in Czech patients.Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks.Application of molecular diagnostics for the detection of Lynch syndrome.hMLH1 promoter methylation and BRAF mutations in high-frequency microsatellite instability colorectal cancers not fulfilling the revised Bethesda guidelines.Colorectal cancer susceptibility loci in a population-based study: Associations with morphological parametersDifferential colorectal carcinogenesis: Molecular basis and clinical relevancePrognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF(V600E) in Patients with Lymph Node-Positive Colon CancerColorectal serrated adenocarcinoma.Microsatellite instability in colorectal cancer-the stable evidence.MLH1 promoter methylation frequency in colorectal cancer patients and related clinicopathological and molecular featuresDeficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancerA review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory.A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy.BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing.Analysis of somatic molecular changes, clinicopathological features, family history, and germline mutations in colorectal cancer families: evidence for efficient diagnosis of HNPCC and for the existence of distinct groups of non-HNPCC familiesA review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectumColorectal cancer: a model for epigenetic tumorigenesis.BRAF gene: From human cancers to developmental syndromes.The CpG island methylator phenotype in colorectal cancer.
P2860
Q21245742-8C88DFC2-6438-4303-9780-9CA23C61C7B0Q24598640-8D151317-A08D-4A23-96A5-91B9BF853B0CQ24681980-5B4A36DC-4789-4DCA-AE19-BF90C7617097Q26751035-5A2A9477-C01B-463F-821D-272E4A12622EQ27004659-8BD01C89-F07A-402A-8E36-FD799766A21CQ27009170-BC605422-1672-4B50-84CE-780944E50DDBQ28070038-751B4D3D-D6E4-4951-B75A-41F2FE2DBFA6Q28083904-092D27C7-A886-4158-B91B-2E4D99AE35C8Q28253670-113669A9-0336-4A94-BD82-1347EF390B08Q28730199-0B233141-DDE8-4FA5-B359-BCC9D75BFB5DQ33658220-3108271E-91C6-43BD-823F-AE652D4143B2Q33658603-882AE988-84D0-48CD-B1A4-8273F0672F3CQ33675252-E33AF99D-2424-4343-A66E-26411116A747Q33775296-90A229DF-88B0-45C8-A134-D51DCA2A65C1Q33836026-C7A7C0B8-E133-4281-A30F-6A21EDA80E91Q33855895-E0A0F763-1793-4803-AC71-87F81141F410Q33861173-8440E474-1845-46E5-95D6-16F7BB027E0FQ33875090-028FC66D-3B40-4BC4-9630-4FD81CA13ADAQ33918280-3D3A8987-C21A-4CF8-949E-020139A9F62FQ34013823-9BB4A99B-EDD4-4E1A-9612-DA1651FE5602Q34077139-B86879CC-F17A-4A4D-8717-E18BCC868C66Q34088809-45E1BBE1-7337-4F9C-A9F1-970A04055F54Q34221477-EA3A8D22-3419-41E1-ACA1-F42372945675Q34358210-E84A24E6-E949-4AE4-9704-87DB5CB90F36Q34391153-F5034C49-6A31-480E-A0B2-D349CB64E48DQ34472453-0C9ED644-D9E6-4346-A59C-9A45D8D3FC5BQ34597935-E404788A-B63B-4EE2-A696-6636F5F54972Q34616565-085540D9-C3C5-4369-A74B-1331F65F0440Q34650716-74823DB4-D779-4ECD-BE51-12AADE61C186Q34986042-93804588-561E-4EB1-B6F4-217ABD73EE2EQ35013990-8C6A8F2A-E2E8-4344-A07E-D96EB16A5F28Q35187723-2B5DCF45-D82A-483E-9CC9-566B16588838Q35233751-8526535C-8CDB-4C59-BB23-4D2D066B429CQ35446668-D95D8406-3D26-4761-A75D-4E5C6470F4E5Q35447238-402C9870-4310-4737-8C5F-04A574539EE6Q35584153-5BD3A7AD-A8DB-4373-BEE0-6FA1D5E397A4Q35596687-CD22A44D-2CCA-4124-B85A-33B03671F668Q35761237-8A43421A-CD44-40D4-A704-A95AA288EBD1Q35802430-988DB472-700A-4D89-A890-798A50E15041Q35855462-8A8539F2-0D32-44FF-9FAF-11820D742247
P2860
BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer
description
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2004
@ast
im Januar 2004 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 2004)
@en
vedecký článok (publikovaný 2004/01/01)
@sk
vědecký článek publikovaný v roce 2004
@cs
wetenschappelijk artikel (gepubliceerd op 2004/01/01)
@nl
наукова стаття, опублікована в січні 2004
@uk
مقالة علمية (نشرت عام 2004)
@ar
name
BRAF mutation is frequently pr ...... nonpolyposis colorectal cancer
@ast
BRAF mutation is frequently pr ...... nonpolyposis colorectal cancer
@en
BRAF mutation is frequently pr ...... nonpolyposis colorectal cancer
@nl
type
label
BRAF mutation is frequently pr ...... nonpolyposis colorectal cancer
@ast
BRAF mutation is frequently pr ...... nonpolyposis colorectal cancer
@en
BRAF mutation is frequently pr ...... nonpolyposis colorectal cancer
@nl
altLabel
BRAF Mutation Is Frequently Pr ...... Nonpolyposis Colorectal Cancer
@en
prefLabel
BRAF mutation is frequently pr ...... nonpolyposis colorectal cancer
@ast
BRAF mutation is frequently pr ...... nonpolyposis colorectal cancer
@en
BRAF mutation is frequently pr ...... nonpolyposis colorectal cancer
@nl
P2093
P3181
P1476
BRAF Mutation Is Frequently Pr ...... Nonpolyposis Colorectal Cancer
@en
BRAF mutation is frequently pr ...... nonpolyposis colorectal cancer
@en
P2093
Brian A Allen
Brindusa Truta
Guoren Deng
Jonathan P Terdiman
Marvin H Sleisenger
Suzanne Crawley
Young S Kim
P3181
P356
10.1158/1078-0432.CCR-1118-3
P407
P577
2004-01-01T00:00:00Z